Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect management

A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma 

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refracotroy Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lanalidomide. MonumenTAL-6

MYRIAM: Clinical Research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma (Myeloma Registry Platform: MYRIAM)

National acute promyelocytic leukemia (APL) observational study NAPOLEON‐Register der Deutschen AML Intergroup

Prospektive nicht-interventionelle Studie (NIS) zur Untersuchung der Wirksamkeit von Tremilimumab & Durvalumab + platinbasierter Chemotherapie (TDC) in Patient:innen mit metastasiertem nicht-plattenepithelialem NSCLC und Risikomutationen.

Prospective multicenter registry for neonates, infants, children, adolescents, and adults with neuroblastic tumours.

Comprehensive assessment of clinical features and biomarkers to identify patients with advanced or metastatic breast cancer for marker driven trials in humans (CATCH).

Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials (COGNITION)